Using State-of-the-Art Technology to Assess the Impact of COVID-19?

Using State-of-the-Art Technology to Assess the Impact of COVID-19?

Pharma is facing the many challenges of COVID-19 head-on. Leading organizations are taking full advantage of today’s sophisticated analytic tools, including state-of-the-art anonymization technologies that seamlessly link patient data across multiple sources, to monitor the impact of COVID-19 on treatments in new ways.


Since the COVID-19 pandemic began, the industry has been primarily focused on understanding the journey of severely ill, older adults requiring hospitalization. More recently, some of the attention has shifted as the number of COVID-19 in younger adults has significantly increased. As unfortunate as this is, longitudinal, cross-over studies assessing the COVID-19 patient journey in a second cohort may provide crucial insight into the virus’s impact on treatments, from onset to recovery and beyond.


Utilizing advanced techniques, researchers can accurately link real-world evidence – Clinical Lab, Pharmacy or Specialty Pharmacy Dispensing and Claims, and EMR data – to obtain an up-to-360° view of the patient journey, helping pharma better understand COVID-19’s disruption on in-line brands. Innovative patient matching technologies, provide an accurate, retrospective view of the patient before their COVID-19 diagnosis – something that can also be inserted into the mix.


Beyond sales, is your company investigating …

  • The impact of COVID-19 on the efficacy of your in-line brands?
  • COVID-19’s impact on the safety of your therapies?
  • Deviations in clinical lab results from the norm of your in-line brands?


If your company is not using the most sophisticated tools to understand the COVID-19 patient journey, know that MSA is here to help. MSA’s HIPAA-compliant, patented technologies provide the high-quality, real-time RWE data required for insightful cross-over studies, and strategic and patient communication planning.  MSA provides the Life Sciences industry the most credentialed, configurable, and trusted de-identification and data management services and solutions.


To learn more about how MSA can help you jump start your company’s COVID-19 research, reach out to the HCDM Team.

Marianne Ryan
No Comments

Post a Comment